FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896578233> ?p ?o ?g. }

• W2896578233 abstract "Alzheimer's disease (AD) prevention trials target an earlier stage of the disease based on the idea that earlier intervention before neuron loss and symptom onset will provide improved outcomes. The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) launched the first AD prevention trial in 2012 in a rare population of dominantly inherited AD mutation carriers who are destined to get the disease with near 100% penetrance. Recruitment was completed in 2015 into two parallel drug arms in the DIAN-TU adaptive prevention trial (DIAN-TU APT) platform. A major goal of public-private prevention trials is to make data available to the research community and this presentation will provide comprehensive results of baseline data. The metrics of establishing the DIAN-TU platform, start-up of sites, launch of the trial, screening, enrollment and close of enrollment measures were analyzed. Baseline demographic, clinical, cognitive, genetic, imaging including MRI, amyloid PIB PET, amyloid AV45 PET, tau AV1451 PET and biomarker results were analyzed according to protocol. Measures were compared to prior findings in the DIAN observational study. A process for DIAN-TU data requests was developed, approved, and activated in 2017. The DIAN-TU APT platform was established in the first year with protocol, site, operational, and multiple partner start-up in this global trial. As sites were activated, enrollment rate increased with rapid enrollment by the end of the study. 194 participants enrolled to successfully meet enrollment goals within projected timelines. Screen fail rate (19%), recruitment source (47% DIAN-obs, 38% DIAN Expanded Registry), and completion rates of all baseline assessments (99-100%) were excellent. This trial provides comprehensive clinical, cognitive, imaging and biomarker data and samples that are being used in the final analyses and are available to address important scientific and medical questions. Clinical prevention trials in AD with multiple AD biomarkers are feasible and can be highly successful, even in a rare population. The results from comprehensive evaluations during trials can provide unique insights into the effects of interventions and promise to accelerate highly effective treatments and preventions for AD." @default.
• W2896578233 created "2018-10-26" @default.
• W2896578233 creator A5000597778 @default.
• W2896578233 creator A5002183686 @default.
• W2896578233 creator A5002320307 @default.
• W2896578233 creator A5005099850 @default.
• W2896578233 creator A5022356562 @default.
• W2896578233 creator A5022462599 @default.
• W2896578233 creator A5025837253 @default.
• W2896578233 creator A5029392216 @default.
• W2896578233 creator A5035502911 @default.
• W2896578233 creator A5035514608 @default.
• W2896578233 creator A5051400478 @default.
• W2896578233 creator A5056358658 @default.
• W2896578233 creator A5062159344 @default.
• W2896578233 creator A5063630764 @default.
• W2896578233 creator A5068373508 @default.
• W2896578233 creator A5068407932 @default.
• W2896578233 creator A5071364728 @default.
• W2896578233 creator A5073392602 @default.
• W2896578233 creator A5080609944 @default.
• W2896578233 creator A5088660280 @default.
• W2896578233 date "2018-07-01" @default.
• W2896578233 modified "2023-10-16" @default.
• W2896578233 title "O1‐02‐03: DIAN‐TU ADAPTIVE PREVENTION TRIAL LAUNCH AND BASELINE DATA" @default.
• W2896578233 doi "https://doi.org/10.1016/j.jalz.2018.06.2338" @default.
• W2896578233 hasPublicationYear "2018" @default.
• W2896578233 type Work @default.
• W2896578233 sameAs 2896578233 @default.
• W2896578233 citedByCount "0" @default.
• W2896578233 crossrefType "journal-article" @default.
• W2896578233 hasAuthorship W2896578233A5000597778 @default.
• W2896578233 hasAuthorship W2896578233A5002183686 @default.
• W2896578233 hasAuthorship W2896578233A5002320307 @default.
• W2896578233 hasAuthorship W2896578233A5005099850 @default.
• W2896578233 hasAuthorship W2896578233A5022356562 @default.
• W2896578233 hasAuthorship W2896578233A5022462599 @default.
• W2896578233 hasAuthorship W2896578233A5025837253 @default.
• W2896578233 hasAuthorship W2896578233A5029392216 @default.
• W2896578233 hasAuthorship W2896578233A5035502911 @default.
• W2896578233 hasAuthorship W2896578233A5035514608 @default.
• W2896578233 hasAuthorship W2896578233A5051400478 @default.
• W2896578233 hasAuthorship W2896578233A5056358658 @default.
• W2896578233 hasAuthorship W2896578233A5062159344 @default.
• W2896578233 hasAuthorship W2896578233A5063630764 @default.
• W2896578233 hasAuthorship W2896578233A5068373508 @default.
• W2896578233 hasAuthorship W2896578233A5068407932 @default.
• W2896578233 hasAuthorship W2896578233A5071364728 @default.
• W2896578233 hasAuthorship W2896578233A5073392602 @default.
• W2896578233 hasAuthorship W2896578233A5080609944 @default.
• W2896578233 hasAuthorship W2896578233A5088660280 @default.
• W2896578233 hasBestOaLocation W28965782332 @default.
• W2896578233 hasConcept C104317684 @default.
• W2896578233 hasConcept C126322002 @default.
• W2896578233 hasConcept C12725497 @default.
• W2896578233 hasConcept C127716648 @default.
• W2896578233 hasConcept C166957645 @default.
• W2896578233 hasConcept C200544954 @default.
• W2896578233 hasConcept C205649164 @default.
• W2896578233 hasConcept C23131810 @default.
• W2896578233 hasConcept C2779134260 @default.
• W2896578233 hasConcept C2908647359 @default.
• W2896578233 hasConcept C4438859 @default.
• W2896578233 hasConcept C505870484 @default.
• W2896578233 hasConcept C535046627 @default.
• W2896578233 hasConcept C55493867 @default.
• W2896578233 hasConcept C71924100 @default.
• W2896578233 hasConcept C86803240 @default.
• W2896578233 hasConcept C99454951 @default.
• W2896578233 hasConceptScore W2896578233C104317684 @default.
• W2896578233 hasConceptScore W2896578233C126322002 @default.
• W2896578233 hasConceptScore W2896578233C12725497 @default.
• W2896578233 hasConceptScore W2896578233C127716648 @default.
• W2896578233 hasConceptScore W2896578233C166957645 @default.
• W2896578233 hasConceptScore W2896578233C200544954 @default.
• W2896578233 hasConceptScore W2896578233C205649164 @default.
• W2896578233 hasConceptScore W2896578233C23131810 @default.
• W2896578233 hasConceptScore W2896578233C2779134260 @default.
• W2896578233 hasConceptScore W2896578233C2908647359 @default.
• W2896578233 hasConceptScore W2896578233C4438859 @default.
• W2896578233 hasConceptScore W2896578233C505870484 @default.
• W2896578233 hasConceptScore W2896578233C535046627 @default.
• W2896578233 hasConceptScore W2896578233C55493867 @default.
• W2896578233 hasConceptScore W2896578233C71924100 @default.
• W2896578233 hasConceptScore W2896578233C86803240 @default.
• W2896578233 hasConceptScore W2896578233C99454951 @default.
• W2896578233 hasIssue "7S_Part_3" @default.
• W2896578233 hasLocation W28965782331 @default.
• W2896578233 hasLocation W28965782332 @default.
• W2896578233 hasOpenAccess W2896578233 @default.
• W2896578233 hasPrimaryLocation W28965782331 @default.
• W2896578233 hasRelatedWork W1985433356 @default.
• W2896578233 hasRelatedWork W2015959761 @default.
• W2896578233 hasRelatedWork W2064353510 @default.
• W2896578233 hasRelatedWork W2093223066 @default.
• W2896578233 hasRelatedWork W2465992156 @default.
• W2896578233 hasRelatedWork W2765980456 @default.
• W2896578233 hasRelatedWork W2940229593 @default.
• W2896578233 hasRelatedWork W2976382042 @default.
• W2896578233 hasRelatedWork W3173176443 @default.

• next